Steven Kanner
Chief Tech/Sci/R&D Officer bei CARIBOU BIOSCIENCES, INC.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Steven B.
Kanner is currently an Independent Director at Specific Biologics, Inc. since 2023 and the Chief Scientific Officer at Caribou Biosciences, Inc. since 2017.
Previously, he worked as the Vice President & Head-Biology at Arrowhead Pharmaceuticals, Inc. from 2013 to 2017.
He completed his undergraduate degree at the University of California, Berkeley and obtained doctorate degrees from the University of Miami and The University of Miami Leonard M.
Miller School of Medicine.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
20.02.2024 | 387 037 ( 0,43% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von Steven Kanner
Unternehmen | Position | Beginn |
---|---|---|
CARIBOU BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 01.06.2017 |
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Director/Board Member | 10.10.2023 |
Ehemalige bekannte Positionen von Steven Kanner
Unternehmen | Position | Ende |
---|---|---|
ARROWHEAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.06.2017 |
Ausbildung von Steven Kanner
University of California, Berkeley | Undergraduate Degree |
The University of Miami Leonard M. Miller School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
CARIBOU BIOSCIENCES, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Commercial Services |